MORE than 100 new medicines have been recommended for approval by the European Medicines Agency (EMA) this year.
Almost 50 of the 114 new medicines have a new active substance which has never been authorised in the European Union before.
Among the new recommendations are a medicine to treat early-onset Alzheimer's disease; the first needle-free and smaller form of adrenaline to treat allergic reactions; the first treatment for tumours associated with Von Hippel--Lindau disease; and two new antibiotic medicines for the treatment of certain severe infections.
EMA also recommended several new vaccines, including one to protect against Chikungunya, and a new mRNA vaccine against lower respiratory tract disease caused by respiratory syncytial virus (RSV).
The Agency also extended the use of an mpox vaccine to protect adolescents from 12 to 17 years of age.
Cancer was once again the strongest therapeutic area, with 28 recommendations for oncology products.
There were also 28 recommendations for new biosimilar products, covering a wide range of diseases, including several types of cancer, osteoporosis, macular degeneration, and more.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jan 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jan 25
